BSECompany Update1d ago · 19 Oct 2026, 02:44 pm

Acquisition of Land for Manufacturing Expansion at Amritsar

Kwality Pharmaceuticals Ltd · 539997

✦ AI Summary▲ PositiveExpansion

Kwality Pharmaceuticals Ltd has acquired 4 acres of land adjacent to its existing manufacturing facility in Amritsar, Punjab, to support its next phase of growth. The company plans to develop a fully automated manufacturing facility with 10 production lines, meeting EU GMP requirements, to meet growing demand for existing and upcoming products, create capacity for future launches, and strengthen its Amritsar manufacturing campus.

Analysis Scores

Earnings Impact8/10
Growth Catalyst9/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment8/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Kwality Pharmaceuticals Ltd - 539997 - Acquisition Of Land For Manuufacturing Expansion At Amritsar

Attachments (1)

📄

0262eb06-f1af-4a40-9305-caf6eabba3d7.pdf

pdf

Download →
View document text
GIN No. L24232PB1983PLC005426 GST No. 03AAACK6458M1ZB Phone : 91-8558820862 (Accounts) : 91-8558820863 (Admin.) D.L. No. 1800-0SP, 1804-B I.E. Code No. 1293001210 : 91-9915743720 (Exports) KWALITY PHARMACEUTICALS LIMITED M.D. Mobile: 91-9814071215, 9814052314 E-mail : export@kwalitypharma.com Regd. Office: Village Nag KaIan, Majitha Road, Amritsar - 143 601 (INDIA) ramesh@kwalitypharma.com Website : www.kwalitypharma.com Date: 19/10/2026 Department of Corporate Services, BSE Limited 25th Floor, P.J. Towers, Dalal Street Mumbai-400001 Scrip Code: 539997 Subject: Acquisition of Land for Manufacturing Expansion at Amritsar, Punjab Kwality Pharmaceuticals Limited is pleased to announce the acquisition of 4 acres of land adjacent to its existing manufacturing facility in Amritsar, Punjab, to support its next phase of growth. The Company plans to develop a fully automated manufacturing facility comprising 4 injectable lines and 6+ lines for tablets, capsules, ophthalmic and other oral solid dosage formulations, designed with due consideration to applicable EU GMP requirements, including Annex 1, wherever relevant. The expansion aims to meet growing demand for existing and upcoming products, create capacity for future launches and bioequivalence-led opportunities, and strengthen the Company's Amritsar manufacturing campus. The project is targeted for completion by Q4 FY2028, with full operations expected by Q2 FY2029, reinforcing the Company's commitment to scalable capacity and sustainable growth. For Kwality Pharma Ramesh Kumar Managing Director